RO 473359
Latest Information Update: 15 Mar 2007
Price :
$50 *
At a glance
- Originator Roche
- Class Antibacterials; Antineoplastics; Quinolones; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 15 Mar 2007 Discontinued - Preclinical for Cancer in Switzerland (unspecified route)
- 18 Feb 2000 No-Development-Reported for Cancer in Switzerland (Unknown route)
- 17 Dec 1996 Preclinical development for Cancer in Switzerland (Unknown route)